Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Cut by Vantage Investment Partners LLC

Vantage Investment Partners LLC decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,480 shares of the medical equipment provider’s stock after selling 2,619 shares during the period. Vantage Investment Partners LLC’s holdings in Intuitive Surgical were worth $8,096,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ISRG. Atomi Financial Group Inc. raised its position in Intuitive Surgical by 19.6% in the first quarter. Atomi Financial Group Inc. now owns 867 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 142 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Intuitive Surgical by 10.4% during the 1st quarter. Meeder Asset Management Inc. now owns 839 shares of the medical equipment provider’s stock worth $335,000 after buying an additional 79 shares during the period. Avantax Advisory Services Inc. raised its stake in Intuitive Surgical by 5.1% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,995 shares of the medical equipment provider’s stock worth $3,989,000 after purchasing an additional 487 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Intuitive Surgical by 51.2% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares in the last quarter. Finally, Patton Fund Management Inc. bought a new stake in Intuitive Surgical during the 1st quarter worth approximately $202,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.1 %

NASDAQ ISRG opened at $535.75 on Tuesday. The company has a market capitalization of $190.82 billion, a price-to-earnings ratio of 86.13, a PEG ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $281.12 and a 1-year high of $542.59. The stock’s 50 day moving average is $493.92 and its two-hundred day moving average is $452.79.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. On average, analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ISRG. Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a report on Friday, October 18th. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Truist Financial lifted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a report on Monday, October 14th. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $513.74.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at $12,391,166.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total transaction of $95,225.76. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,788,899.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,006 shares of company stock valued at $33,727,766 over the last three months. 0.90% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.